Shares of Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) traded down 4.6% during trading on Friday . The stock traded as low as $2.41 and last traded at $2.42. 355,817 shares were traded during mid-day trading, a decline of 56% from the average session volume of 809,771 shares. The stock had previously closed at $2.54.
Wall Street Analyst Weigh In
Separately, Cormark raised shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Strong Buy".
Check Out Our Latest Research Report on Curaleaf
Curaleaf Trading Down 6.6%
The company has a debt-to-equity ratio of 1.00, a current ratio of 1.47 and a quick ratio of 0.70. The firm has a market capitalization of $1.59 billion, a PE ratio of -7.41 and a beta of 0.78. The company's fifty day simple moving average is $2.38 and its 200-day simple moving average is $1.40.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.61%. As a group, sell-side analysts expect that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current fiscal year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.